


# FEE TRANSMITTAL

Patent fees are subject to annual revision.

## Complete if Known

Application Number	09/086,327
Filing Date	May 28, 1998
First Named Inventor	Durette, et al
Examiner Name	Lukton
Group Art Unit	1654
Attorney Docket Number	19965Y

TOTAL AMOUNT OF PAYMENT \$240



## METHOD OF PAYMENT (Check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 13-2755

Deposit Account Name Merck & Co., Inc.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	690	Utility filing fee	
106	310	Design filing fee	
108	690	Reissue filing fee	
114	150	Provisional filing fee	
SUBTOTAL(1)			\$0

### 2. EXTRA CLAIM FEES

	Extra	Fee from below	Fee Paid
Total Claims	20	0	0
Independent Claims	3	0	0
Multiple Dependent Claims			

\*\*or number previously paid, if greater; For Reissues, see below

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
103	18	Claims in excess of 20	
102	78	Independent claims in excess of 3	
104	260	Multiple dependent claims	
109	78	**Reissue independent claims over original patent	
110	18	**Reissue claims in excess of 20 and over original patent	
SUBTOTAL(2)			\$0

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	Surcharge - late filing fee or oath	
147	2,520	For filing a request for reexamination	
115	110	Extension for reply within first month	
116	380	Extension for reply within second month	
117	870	Extension for reply within third month	
118	1,360	Extension for reply within fourth month	
128	1,850	Extension for reply within fifth month	
119	300	Notice of Appeal	
120	300	Filing a brief in support of an appeal	
121	260	Request for oral hearing	
140	110	Petition to revive - unavoidable	
141	1,210	Petition to revive - unintentional	
142	1,210	Utility issue fee (or reissue)	
143	430	Design issue fee	
122	130	Petitions to the Commissioner	
123	50	Petitions related to provisional applications	
126	240	Submission of Information Disclosure Statement	240
581	40	Recording each patent assignment per property (times number of properties)	
146	690	Filing a submission after final rejection (37 CFR 1.129(a))	
149	690	For each additional invention to be examined (37 CFR 1.129(b))	
Other fee (specify)			
Other fee (specify)			
SUBTOTAL(3)			\$240

## SUBMITTED BY

## Complete (if applicable)

Typed or Printed Name Mollie M. Yang

Reg. Number 32,718


Signature

*Mollie M. Yang*

Date 02/22/2000

Deposit Account User ID

Application Number: 09/086,327  
Filing Date: 05/28/1998  
First Named Inventor: Durette, et al.  
Group Art Unit: 1654  
Examiner Name: Lukton  
Attorney Docket Number: 19965Y



### FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

**MERCK & CO., INC.**

MAILED BY

*Hollie Star*

DATE 02/22/2000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Durette, et al.

Serial No. 09/086,327

Filed: May 28, 1998

For: Heterocyclic Amide Compounds as Cell  
Adhesion Inhibitors

Art Unit: 1654

Examiner: Lukton

Assistant Commissioner for Patents  
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

02/28/2000 NPRASASD 00000034 132755 09086327

01 FC:126 240.00 CH

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK &amp; CO., INC.

TECH CENTER 1600/2900

By

Date

2/28/00

# INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☒ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,



By: Mollie M. Yang  
Attorney For Applicant(s)

Reg. No. 32,718  
MERCK & CO., INC.  
Patent Dept., RY60-30  
P.O. Box 2000  
Rahway, N.J. 07065-0907  
(732)594- 6343  
Date: February 22, 2000